Table 3

Diagnostic performance of non-invasive tests for advanced fibrosis (F3–F4)

LSM by VCTE
(n=5489)
FIB-4
(n=5393)
NFS
(n=3248)
APRI
(n=5477)
AST/ALT
(n=5434)
Advanced fibrosis, %3030293030
AUROC0.85 (0.84–0.86)0.76 (0.74–0.77)0.73 (0.71–0.75)0.70 (0.69–0.72)0.64 (0.62–0.65)
YI90% Se90% SpYI90% Se90% SpYI90% Se90% SpYI90% Se90% SpYI90% Se90% Sp
Threshold9.17.412.11.440.882.31−1.39−2.550.280.490.290.910.640.511.34
Sensitivity, %77
(75–79)
90
(89–91)
55
(52–57)
69
(67–72)
90
(88–91)
38
(36–41)
75
(72–78)
90
(88–92)
29
(26–32)
67
(64–69)
90
(89–92)
32
(30–34)
75
(73–77)
90
(87–91)
16
(14–18)
Specificity, %78
(76–79)
60
(59–61)
90
(89–91)
70
(69–72)
39
(37–40)
90
(89–91)
63
(61–65)
36
(33–37)
90
(89–91)
63
(62–65)
29
(28–30)
90
(89–91)
47
(45–48)
25
(23–26)
90
(89–91)
Misclassified, %22
(22–23)
31
(31–32)
21
(20–21)
30
(30–31)
46
(46–47)
26
(25–26)
34
(34–36)
48
(49–50)
28
(28–29)
36
(36–37)
53
(53–54)
27
(27–28)
45
(45–46)
56
(56–57)
32
(32–33)
  • For each non-invasive test thresholds were selected according to Youden’s index (YI), and fixed at 90% sensitivity (90% Se) and 90% specificity (90% Sp). 95% CIs were estimated with 500 bootstrap replicates.

  • ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; FIB-4, Fibrosis-4 Index; LSM, liver stiffness measurement; NFS, NAFLD (non-alcoholic fatty liver disease) Fibrosis Score; VCTE, vibration controlled transient elastography.